proteins Search Results


rhesus monkey il 1 beta  (R&D Systems)
92
R&D Systems rhesus monkey il 1 beta
Rhesus Monkey Il 1 Beta, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rhesus monkey il 1 beta/product/R&D Systems
Average 92 stars, based on 1 article reviews
rhesus monkey il 1 beta - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier
dll4  (R&D Systems)
94
R&D Systems dll4
Dll4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dll4/product/R&D Systems
Average 94 stars, based on 1 article reviews
dll4 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
vegf a 165  (R&D Systems)
94
R&D Systems vegf a 165
Vegf A 165, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vegf a 165/product/R&D Systems
Average 94 stars, based on 1 article reviews
vegf a 165 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
tumor necrosis factor α  (R&D Systems)
92
R&D Systems tumor necrosis factor α
Tumor Necrosis Factor α, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tumor necrosis factor α/product/R&D Systems
Average 92 stars, based on 1 article reviews
tumor necrosis factor α - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier
rxn  (Boston Biochem)
96
Boston Biochem rxn
List of antibodies and related reagents
Rxn, supplied by Boston Biochem, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rxn/product/Boston Biochem
Average 96 stars, based on 1 article reviews
rxn - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier
recombinant human ccl1  (R&D Systems)
94
R&D Systems recombinant human ccl1
CCR8 expression in tumor T reg cells and characterization of anti-CCR8 antibodies . (A) Representative histogram plot depicting expression of CCR8 on 4-1BB + and 4-1BB − CD4 + Foxp3 − T EFF population in MC38 tumors. (B) Representative histogram plot depicting expression of CCR8 on CCR7 + and CCR7 − CD8 + T cells in MC38 tumors. (C) Flow cytometry analysis of tumor-infiltrating T reg cells across multiple mouse tumor models shown as representative FACS plots (left) and frequencies in tumors and peripheral lymphoid organs (right). *, P = 0.0250; ****, P < 0.0001; two-way ANOVA with Tukey’s post-hoc analysis. (D) Flow cytometry analysis of CCR8 expression on immune cell types (Foxp3 + T reg cells, Foxp3 − T effectors, CD8 + , NKp46 + NK, CD19 + B, and CD11b + ) in tumors and peripheral lymphoid tissues across tumor models. (E) In vitro chemotaxis assay evaluating the ability of CCR8-depleting and -nondepleting antibodies to block 100 pM <t>CCL1-induced</t> chemotaxis. (F) Bar graph comparing IC 50 values from the chemotaxis assay testing CCR8-depleting and -nondepleting antibodies ( n = 6). (G) Pharmacokinetic assessment of serum antibody concentration after single-dose administration of CCR8-depleting and -nondepleting antibodies (10 mg/kg i.p.). (H) Serum concentration at 72 h of animals treated as in G. DLN, draining LN; SPL, spleen; MFI, mean fluorescence intensity.
Recombinant Human Ccl1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human ccl1/product/R&D Systems
Average 94 stars, based on 1 article reviews
recombinant human ccl1 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
recombinant human il 13 protein  (R&D Systems)
95
R&D Systems recombinant human il 13 protein
CCR8 expression in tumor T reg cells and characterization of anti-CCR8 antibodies . (A) Representative histogram plot depicting expression of CCR8 on 4-1BB + and 4-1BB − CD4 + Foxp3 − T EFF population in MC38 tumors. (B) Representative histogram plot depicting expression of CCR8 on CCR7 + and CCR7 − CD8 + T cells in MC38 tumors. (C) Flow cytometry analysis of tumor-infiltrating T reg cells across multiple mouse tumor models shown as representative FACS plots (left) and frequencies in tumors and peripheral lymphoid organs (right). *, P = 0.0250; ****, P < 0.0001; two-way ANOVA with Tukey’s post-hoc analysis. (D) Flow cytometry analysis of CCR8 expression on immune cell types (Foxp3 + T reg cells, Foxp3 − T effectors, CD8 + , NKp46 + NK, CD19 + B, and CD11b + ) in tumors and peripheral lymphoid tissues across tumor models. (E) In vitro chemotaxis assay evaluating the ability of CCR8-depleting and -nondepleting antibodies to block 100 pM <t>CCL1-induced</t> chemotaxis. (F) Bar graph comparing IC 50 values from the chemotaxis assay testing CCR8-depleting and -nondepleting antibodies ( n = 6). (G) Pharmacokinetic assessment of serum antibody concentration after single-dose administration of CCR8-depleting and -nondepleting antibodies (10 mg/kg i.p.). (H) Serum concentration at 72 h of animals treated as in G. DLN, draining LN; SPL, spleen; MFI, mean fluorescence intensity.
Recombinant Human Il 13 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human il 13 protein/product/R&D Systems
Average 95 stars, based on 1 article reviews
recombinant human il 13 protein - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
granulocyte macrophage colony  (R&D Systems)
92
R&D Systems granulocyte macrophage colony
CCR8 expression in tumor T reg cells and characterization of anti-CCR8 antibodies . (A) Representative histogram plot depicting expression of CCR8 on 4-1BB + and 4-1BB − CD4 + Foxp3 − T EFF population in MC38 tumors. (B) Representative histogram plot depicting expression of CCR8 on CCR7 + and CCR7 − CD8 + T cells in MC38 tumors. (C) Flow cytometry analysis of tumor-infiltrating T reg cells across multiple mouse tumor models shown as representative FACS plots (left) and frequencies in tumors and peripheral lymphoid organs (right). *, P = 0.0250; ****, P < 0.0001; two-way ANOVA with Tukey’s post-hoc analysis. (D) Flow cytometry analysis of CCR8 expression on immune cell types (Foxp3 + T reg cells, Foxp3 − T effectors, CD8 + , NKp46 + NK, CD19 + B, and CD11b + ) in tumors and peripheral lymphoid tissues across tumor models. (E) In vitro chemotaxis assay evaluating the ability of CCR8-depleting and -nondepleting antibodies to block 100 pM <t>CCL1-induced</t> chemotaxis. (F) Bar graph comparing IC 50 values from the chemotaxis assay testing CCR8-depleting and -nondepleting antibodies ( n = 6). (G) Pharmacokinetic assessment of serum antibody concentration after single-dose administration of CCR8-depleting and -nondepleting antibodies (10 mg/kg i.p.). (H) Serum concentration at 72 h of animals treated as in G. DLN, draining LN; SPL, spleen; MFI, mean fluorescence intensity.
Granulocyte Macrophage Colony, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/granulocyte macrophage colony/product/R&D Systems
Average 92 stars, based on 1 article reviews
granulocyte macrophage colony - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier
recombinant biotinylated sars cov 2 spike  (R&D Systems)
93
R&D Systems recombinant biotinylated sars cov 2 spike
CCR8 expression in tumor T reg cells and characterization of anti-CCR8 antibodies . (A) Representative histogram plot depicting expression of CCR8 on 4-1BB + and 4-1BB − CD4 + Foxp3 − T EFF population in MC38 tumors. (B) Representative histogram plot depicting expression of CCR8 on CCR7 + and CCR7 − CD8 + T cells in MC38 tumors. (C) Flow cytometry analysis of tumor-infiltrating T reg cells across multiple mouse tumor models shown as representative FACS plots (left) and frequencies in tumors and peripheral lymphoid organs (right). *, P = 0.0250; ****, P < 0.0001; two-way ANOVA with Tukey’s post-hoc analysis. (D) Flow cytometry analysis of CCR8 expression on immune cell types (Foxp3 + T reg cells, Foxp3 − T effectors, CD8 + , NKp46 + NK, CD19 + B, and CD11b + ) in tumors and peripheral lymphoid tissues across tumor models. (E) In vitro chemotaxis assay evaluating the ability of CCR8-depleting and -nondepleting antibodies to block 100 pM <t>CCL1-induced</t> chemotaxis. (F) Bar graph comparing IC 50 values from the chemotaxis assay testing CCR8-depleting and -nondepleting antibodies ( n = 6). (G) Pharmacokinetic assessment of serum antibody concentration after single-dose administration of CCR8-depleting and -nondepleting antibodies (10 mg/kg i.p.). (H) Serum concentration at 72 h of animals treated as in G. DLN, draining LN; SPL, spleen; MFI, mean fluorescence intensity.
Recombinant Biotinylated Sars Cov 2 Spike, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant biotinylated sars cov 2 spike/product/R&D Systems
Average 93 stars, based on 1 article reviews
recombinant biotinylated sars cov 2 spike - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
met protein  (R&D Systems)
93
R&D Systems met protein
CCR8 expression in tumor T reg cells and characterization of anti-CCR8 antibodies . (A) Representative histogram plot depicting expression of CCR8 on 4-1BB + and 4-1BB − CD4 + Foxp3 − T EFF population in MC38 tumors. (B) Representative histogram plot depicting expression of CCR8 on CCR7 + and CCR7 − CD8 + T cells in MC38 tumors. (C) Flow cytometry analysis of tumor-infiltrating T reg cells across multiple mouse tumor models shown as representative FACS plots (left) and frequencies in tumors and peripheral lymphoid organs (right). *, P = 0.0250; ****, P < 0.0001; two-way ANOVA with Tukey’s post-hoc analysis. (D) Flow cytometry analysis of CCR8 expression on immune cell types (Foxp3 + T reg cells, Foxp3 − T effectors, CD8 + , NKp46 + NK, CD19 + B, and CD11b + ) in tumors and peripheral lymphoid tissues across tumor models. (E) In vitro chemotaxis assay evaluating the ability of CCR8-depleting and -nondepleting antibodies to block 100 pM <t>CCL1-induced</t> chemotaxis. (F) Bar graph comparing IC 50 values from the chemotaxis assay testing CCR8-depleting and -nondepleting antibodies ( n = 6). (G) Pharmacokinetic assessment of serum antibody concentration after single-dose administration of CCR8-depleting and -nondepleting antibodies (10 mg/kg i.p.). (H) Serum concentration at 72 h of animals treated as in G. DLN, draining LN; SPL, spleen; MFI, mean fluorescence intensity.
Met Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/met protein/product/R&D Systems
Average 93 stars, based on 1 article reviews
met protein - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
recombinant feline gm csf  (R&D Systems)
90
R&D Systems recombinant feline gm csf
CCR8 expression in tumor T reg cells and characterization of anti-CCR8 antibodies . (A) Representative histogram plot depicting expression of CCR8 on 4-1BB + and 4-1BB − CD4 + Foxp3 − T EFF population in MC38 tumors. (B) Representative histogram plot depicting expression of CCR8 on CCR7 + and CCR7 − CD8 + T cells in MC38 tumors. (C) Flow cytometry analysis of tumor-infiltrating T reg cells across multiple mouse tumor models shown as representative FACS plots (left) and frequencies in tumors and peripheral lymphoid organs (right). *, P = 0.0250; ****, P < 0.0001; two-way ANOVA with Tukey’s post-hoc analysis. (D) Flow cytometry analysis of CCR8 expression on immune cell types (Foxp3 + T reg cells, Foxp3 − T effectors, CD8 + , NKp46 + NK, CD19 + B, and CD11b + ) in tumors and peripheral lymphoid tissues across tumor models. (E) In vitro chemotaxis assay evaluating the ability of CCR8-depleting and -nondepleting antibodies to block 100 pM <t>CCL1-induced</t> chemotaxis. (F) Bar graph comparing IC 50 values from the chemotaxis assay testing CCR8-depleting and -nondepleting antibodies ( n = 6). (G) Pharmacokinetic assessment of serum antibody concentration after single-dose administration of CCR8-depleting and -nondepleting antibodies (10 mg/kg i.p.). (H) Serum concentration at 72 h of animals treated as in G. DLN, draining LN; SPL, spleen; MFI, mean fluorescence intensity.
Recombinant Feline Gm Csf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant feline gm csf/product/R&D Systems
Average 90 stars, based on 1 article reviews
recombinant feline gm csf - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
rhnrg1  (R&D Systems)
94
R&D Systems rhnrg1
CCR8 expression in tumor T reg cells and characterization of anti-CCR8 antibodies . (A) Representative histogram plot depicting expression of CCR8 on 4-1BB + and 4-1BB − CD4 + Foxp3 − T EFF population in MC38 tumors. (B) Representative histogram plot depicting expression of CCR8 on CCR7 + and CCR7 − CD8 + T cells in MC38 tumors. (C) Flow cytometry analysis of tumor-infiltrating T reg cells across multiple mouse tumor models shown as representative FACS plots (left) and frequencies in tumors and peripheral lymphoid organs (right). *, P = 0.0250; ****, P < 0.0001; two-way ANOVA with Tukey’s post-hoc analysis. (D) Flow cytometry analysis of CCR8 expression on immune cell types (Foxp3 + T reg cells, Foxp3 − T effectors, CD8 + , NKp46 + NK, CD19 + B, and CD11b + ) in tumors and peripheral lymphoid tissues across tumor models. (E) In vitro chemotaxis assay evaluating the ability of CCR8-depleting and -nondepleting antibodies to block 100 pM <t>CCL1-induced</t> chemotaxis. (F) Bar graph comparing IC 50 values from the chemotaxis assay testing CCR8-depleting and -nondepleting antibodies ( n = 6). (G) Pharmacokinetic assessment of serum antibody concentration after single-dose administration of CCR8-depleting and -nondepleting antibodies (10 mg/kg i.p.). (H) Serum concentration at 72 h of animals treated as in G. DLN, draining LN; SPL, spleen; MFI, mean fluorescence intensity.
Rhnrg1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rhnrg1/product/R&D Systems
Average 94 stars, based on 1 article reviews
rhnrg1 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

Image Search Results


List of antibodies and related reagents

Journal: Oncogene

Article Title: Identification of a novel EphB4 phosphodegron regulated by the autocrine IGFII/IR A axis in malignant mesothelioma

doi: 10.1038/s41388-019-0854-y

Figure Lengend Snippet: List of antibodies and related reagents

Article Snippet: Ubiquitin, human synthetic , n/a , 800 ng/rxn , Boston Biochemical , U-100H.

Techniques: Concentration Assay, Ubiquitin Proteomics

CCR8 expression in tumor T reg cells and characterization of anti-CCR8 antibodies . (A) Representative histogram plot depicting expression of CCR8 on 4-1BB + and 4-1BB − CD4 + Foxp3 − T EFF population in MC38 tumors. (B) Representative histogram plot depicting expression of CCR8 on CCR7 + and CCR7 − CD8 + T cells in MC38 tumors. (C) Flow cytometry analysis of tumor-infiltrating T reg cells across multiple mouse tumor models shown as representative FACS plots (left) and frequencies in tumors and peripheral lymphoid organs (right). *, P = 0.0250; ****, P < 0.0001; two-way ANOVA with Tukey’s post-hoc analysis. (D) Flow cytometry analysis of CCR8 expression on immune cell types (Foxp3 + T reg cells, Foxp3 − T effectors, CD8 + , NKp46 + NK, CD19 + B, and CD11b + ) in tumors and peripheral lymphoid tissues across tumor models. (E) In vitro chemotaxis assay evaluating the ability of CCR8-depleting and -nondepleting antibodies to block 100 pM CCL1-induced chemotaxis. (F) Bar graph comparing IC 50 values from the chemotaxis assay testing CCR8-depleting and -nondepleting antibodies ( n = 6). (G) Pharmacokinetic assessment of serum antibody concentration after single-dose administration of CCR8-depleting and -nondepleting antibodies (10 mg/kg i.p.). (H) Serum concentration at 72 h of animals treated as in G. DLN, draining LN; SPL, spleen; MFI, mean fluorescence intensity.

Journal: The Journal of Experimental Medicine

Article Title: STARTRAC analyses of scRNAseq data from tumor models reveal T cell dynamics and therapeutic targets

doi: 10.1084/jem.20201329

Figure Lengend Snippet: CCR8 expression in tumor T reg cells and characterization of anti-CCR8 antibodies . (A) Representative histogram plot depicting expression of CCR8 on 4-1BB + and 4-1BB − CD4 + Foxp3 − T EFF population in MC38 tumors. (B) Representative histogram plot depicting expression of CCR8 on CCR7 + and CCR7 − CD8 + T cells in MC38 tumors. (C) Flow cytometry analysis of tumor-infiltrating T reg cells across multiple mouse tumor models shown as representative FACS plots (left) and frequencies in tumors and peripheral lymphoid organs (right). *, P = 0.0250; ****, P < 0.0001; two-way ANOVA with Tukey’s post-hoc analysis. (D) Flow cytometry analysis of CCR8 expression on immune cell types (Foxp3 + T reg cells, Foxp3 − T effectors, CD8 + , NKp46 + NK, CD19 + B, and CD11b + ) in tumors and peripheral lymphoid tissues across tumor models. (E) In vitro chemotaxis assay evaluating the ability of CCR8-depleting and -nondepleting antibodies to block 100 pM CCL1-induced chemotaxis. (F) Bar graph comparing IC 50 values from the chemotaxis assay testing CCR8-depleting and -nondepleting antibodies ( n = 6). (G) Pharmacokinetic assessment of serum antibody concentration after single-dose administration of CCR8-depleting and -nondepleting antibodies (10 mg/kg i.p.). (H) Serum concentration at 72 h of animals treated as in G. DLN, draining LN; SPL, spleen; MFI, mean fluorescence intensity.

Article Snippet: Recombinant human CCL1 (R&D Systems) was prepared at suboptimal concentration of 100 pM and added to the bottom Transwell chambers at 100 μl per well.

Techniques: Expressing, Flow Cytometry, In Vitro, Chemotaxis Assay, Blocking Assay, Concentration Assay, Fluorescence